U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H58N4O12
Molecular Weight 822.9402
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of RIFAMPIN

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(\C=N\N5CCN(C)CC5)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C

InChI

InChIKey=JQXXHWHPUNPDRT-WLSIYKJHSA-N
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

HIDE SMILES / InChI
Molecular Formula C43H58N4O12
Molecular Weight 822.9402
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 1
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:49:50 UTC 2023
Edited
by admin
on Sat Dec 16 15:49:50 UTC 2023
Record UNII
VJT6J7R4TR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIFAMPIN
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
RIFALDAZINE
Common Name English
RIFAMPICIN [JAN]
Common Name English
BA-41166/E
Code English
RIMACTAN
Brand Name English
RIFATER COMPONENT RIFAMPIN
Common Name English
RIFAMPIN COMPONENT OF RIFATER
Common Name English
NSC-113926
Code English
RIFAMPICIN
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
BA-41166E
Code English
RIMACTANE
Brand Name English
RIFAMPICIN [EP IMPURITY]
Common Name English
RIFADINE
Brand Name English
NIH-10782
Code English
RIFAMYCIN AMP
Common Name English
3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN
Systematic Name English
RIFA
Brand Name English
RIFAMPICIN [IARC]
Common Name English
RIFAMPIN COMPONENT OF RIFAMATE
Common Name English
RIFAMPIN [MI]
Common Name English
RIFAMPICINUM [WHO-IP LATIN]
Common Name English
L-5103 LEPETIT
Code English
RIFAPRODIN
Brand Name English
RIFAMYCIN, 3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)-
Common Name English
RIFAMPICIN [MART.]
Common Name English
BA 41166/E
Code English
RIFOLDIN
Brand Name English
RIFAMPICIN [WHO-IP]
Common Name English
RIFAPIAM
Brand Name English
RIFAMPIN [USAN]
Common Name English
RIFAMYCIN AMP [MI]
Common Name English
L-5103
Code English
rifampicin [INN]
Common Name English
L-5103-LEPETIT
Code English
RIFAMATE COMPONENT RIFAMPIN
Common Name English
RIFAMPIN [ORANGE BOOK]
Common Name English
R/AMP
Common Name English
5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate
Systematic Name English
ABRIFAM
Brand Name English
Rifampicin [WHO-DD]
Common Name English
EREMFAT
Brand Name English
RIFADIN
Brand Name English
RIFAMPIN [USP MONOGRAPH]
Common Name English
RIFAMPICIN [EP MONOGRAPH]
Common Name English
RIFAMPIN [HSDB]
Common Name English
RIFALDIN
Brand Name English
RIFAMPIN [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 6585
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/PYR/RIF)
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NDF-RT N0000175500
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/RIF)
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/PYR/RIF)
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
FDA ORPHAN DRUG 7685
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.3
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-VATC QJ04AM05
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ATC J04AB02
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ATC J04AM07
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ATC J04AM02
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ATC J04AM05
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NCI_THESAURUS C280
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
FDA ORPHAN DRUG 928022
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-VATC QJ04AB02
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-VATC QJ04AM02
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ATC J04AM06
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/RIF)
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-VATC QJ04AM06
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NDF-RT N0000007911
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
NCI_THESAURUS C25995
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
WHO-VATC QJ54AB02
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
LIVERTOX NBK548314
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
Code System Code Type Description
CHEBI
28077
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
CHEBI
71365
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL374478
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
WIKIPEDIA
RIFAMPICIN
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
RIFAMPIN
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY Description: A brick red to red-brown, crystalline powder. Solubility: Very slightly to slightly soluble in water; soluble in methanol R; slightly soluble in acetone R, ethanol (~750 g/l) TS, and ether R. Category: Antileprosy drug; antituberculosis drug. Storage: Rifampicin should be kept in a tightly closed container or in an atmosphere of nitrogen, protected from light. Additional information: Rifampicin exhibits polymorphism. Definition: Rifampicin contains not less than 97.0% and not more than 102.0% of C43H58N4O12, calculated with reference to the dried substance.
SMS_ID
100000080561
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
DAILYMED
VJT6J7R4TR
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID6021244
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
RXCUI
9384
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY RxNorm
INN
2323
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
HSDB
3181
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
PUBCHEM
135398735
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
LACTMED
Rifampin
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
RS_ITEM_NUM
1604009
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
CAS
845504-52-1
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
ALTERNATIVE
MESH
D012293
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
IUPHAR
2765
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
ECHA (EC/EINECS)
236-312-0
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
NCI_THESAURUS
C811
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
EVMPD
SUB10309MIG
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
MERCK INDEX
m9611
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
2377
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
DRUG BANK
DB01045
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
CAS
13292-46-1
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
NSC
113926
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
FDA UNII
VJT6J7R4TR
Created by admin on Sat Dec 16 15:49:54 UTC 2023 , Edited by admin on Sat Dec 16 15:49:54 UTC 2023
PRIMARY
Related Record Type Details
OATP1B1
TRANSPORTER -> SUBSTRATE
OAT-1
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> INDUCER
POTENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INDUCER
CYTOCHROME P450 2C8
METABOLIC ENZYME -> INDUCER
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INDUCER
POTENT
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INDUCER
OATP-8
TRANSPORTER -> SUBSTRATE
MRP-3
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 3A5
METABOLIC ENZYME -> INDUCER
OATP1B1
TRANSPORTER -> INHIBITOR
BSEP
TRANSPORTER -> INHIBITOR
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7
METABOLIC ENZYME -> INDUCER
DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA (M. TUBERCULOSIS)
TARGET -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INDUCER
MRP-1
TRANSPORTER -> INHIBITOR
OATP-B
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: Bromsulphthalein (BSP)
SOLUTE CARRIER FAMILY 21 MEMBER 3
TRANSPORTER -> INHIBITOR
CAN BE USED FOR IN-VIVO STUDIES OF TRANSPORTER
IN-VIVO
MRP-2
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of 25-DESACETYLRIFAMPIN
METABOLITE -> PARENT
Related Record Type Details
Structure of RIFAMPICIN N-OXIDE
IMPURITY -> PARENT
Structure of RIFAMPICIN QUINONE
IMPURITY -> PARENT
Related Record Type Details
Structure of RIFAMPIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Duration of Action PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: N. MENINGIDITIS

Biological Half-life PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: END-STAGE RENAL DISEASE

Tmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: ORAL

Cmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: ORAL

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

POPULATION: PEDIATRICS

Biological Half-life PHARMACOKINETIC POPULATION: HEPATIC IMPAIRMENT

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: IV

POPULATION: PEDIATRICS

Cmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL PATHOGEN: N. MENINGIDITIS

SUSCEPTIBILITY: SUSCEPTIBLE

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL PATHOGEN: N. MENINGIDITIS

SUSCEPTIBILITY: INTERMEDIATE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966